KRAS and colorectal carcinoma: While the molecular mechanisms of EMICORON activity against KRAS-mutated tumors need to be fully elucidated, our data on HCT-116 cells showing the effect of EMICORON in down-regulating both KRAS mRNA and protein expression accompanied by the strong in vivo antitumor efficacy against a panel of KRAS-mutated CRC PDXs, suggest the potential of EMICORON for the clinical application of EMICORON in this mCRC clinical setting.